Cumberland Pharmaceuticals Inc. CPIX
Biotechnology: Pharmaceutical Preparations · IPO 2009 · data as of November 13, 2026
Cumberland Pharmaceuticals Inc. (CPIX) is a healthcare company listed in the US with a market value of about $88M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of $69M, a net margin of 203.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 1.3, 5-year revenue growth of 4% a year, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% below the current price.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2009. Revenue went from $37M in 2014 to $45M in 2025, growth of about 1.7% a year. It was profitable in 0 of the last 10 years in our data. It spends 13% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34M | $45M | $38M | $40M | $42M | $36M | $37M | $34M | $29M | $41M | $33M |
| Net income | $69M | -$3M | -$6M | -$6M | -$6M | -$4M | -$3M | -$4M | -$7M | -$8M | -$944683 |
| Free cash flow | -$987321 | $5M | -$678647 | $6M | $8M | $6M | $5M | $3M | $3M | -$833674 | $438606 |
| EPS (diluted) | $4.47 | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
| Net margin | 203.7% | -6.4% | -17.1% | -15.9% | -13.3% | -9.8% | -8.9% | -10.3% | -23.7% | -19.4% | -2.9% |
| ROIC | — | -6.3% | -14.8% | -15.7% | -7.9% | -10.3% | -7.9% | -12.7% | -11.6% | -4.4% | -1.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Cumberland Pharmaceuticals’s P/E ratio?
About 1.3, based on the last twelve months of diluted earnings per share.
Is Cumberland Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 3% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cumberland Pharmaceuticals pay a dividend?
Not currently.
Is Cumberland Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Cumberland Pharmaceuticals scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.